RxDoctor Payments DataLook up a doctor →

Srikant Kondapaneni, MD

Internal Medicine · Englewood, NJNPI 1447273867

Payments from drug & device makers

$152,197in general payments, 2019–2025

Across 628 payments — averaging $242.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$140K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Harmony Biosciences LLC$1K
  • Hill-rom Company, Inc$875
  • Jazz Pharmaceuticals Inc.$854
  • GSK$749
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron8$140,353
Actelion Pharmaceuticals US, Inc.61$1,150
Harmony Biosciences LLC52$1,030
Hill-rom Company, Inc1$875
Jazz Pharmaceuticals Inc.58$854
GSK49$749
Boehringer Ingelheim44$624
AstraZeneca(2 entities)32$619
Avadel CNS Pharmaceuticals, LLC38$576
Mylan Specialty L.p.46$542
Inspire Medical Systems, Inc.13$488
Grifols USA, LLC18$431
Axsome Therapeutics, Inc.33$357
Pulmonx Corporation3$348
Insmed, Inc.11$215
Philips North America LLC13$207
United Therapeutics Corporation11$185
Galvanize Therapeutics, Inc1$177
Inari Medical, Inc.2$170
Mallinckrodt Hospital Products Inc.9$138
Bayer2$138
Novo Nordisk9$137
Electromed, Inc.8$135
Johnson & Johnson6$122
Amgen8$117
Viatris Specialty LLC6$115
Pfizer8$114
Sunovion Pharmaceuticals Inc.8$112
Merck8$109
Takeda Pharmaceuticals U.S.A., Inc.6$95
Xeris Pharmaceuticals, Inc.5$85
Genentech USA, Inc.5$77
Lilly USA, LLC4$73
Baxter Healthcare3$67
Mannkind Corporation4$56
Covis Pharma GmbH3$50
Teva Pharmaceuticals USA, Inc.3$44
Advanced Respiratory, Inc2$36
Vifor Pharma, Inc.2$33
Corcept Therapeutics2$32
Sanofi-aventis U.S. LLC2$29
Amarin Pharma, Inc.2$26
Aerin Medical Inc.1$24
Exact Sciences1$23
Abbott1$19
Resmed Corp1$19
UCB, Inc.1$18
Neurocrine Biosciences, Inc.1$17
Optinose US, Inc.1$17
Ascendis Pharma Endocrinology Inc1$16
Verona Pharma, Inc.1$16
Zealand Pharma US, Inc.1$16
Arbor Pharmaceuticals, Inc.1$15
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$15
Daiichi Sankyo Inc.1$15
Ultragenyx Pharmaceutical Inc.1$14
Sanofi1$14
Regeneron Healthcare Solutions, Inc.1$14
Azurity Pharmaceuticals, Inc.1$13
Nabriva Therapeutics, PLC1$12

How this compares

$152,197 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$223,576
Medicare patients
822
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →